Basic Information
| LncRNA/CircRNA Name | lnc-PCDH9-13:1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR |
| Sample | hepatocellular carcinoma tissues, cell lines (HepG2, HepG2.2.15 ) |
| Expression Pattern | up-regulated |
| Function Description | Lnc-PCDH9-13:1 was significantly elevated in HCC tissues, plasma and saliva of HCC patients compared with healthy controls and groups of several benign liver diseases and other leading cancers. Its level was significantly reduced after curative hepatectomy but significantly elevated again if HCC recurrence occurred. the overexpression of lnc-PCDH9-13:1 promotes cell proliferation and migration in vitro. |
| Pubmed ID | 30045829 |
| Year | 2018 |
| Title | Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. |
External Links
| Links for lnc-PCDH9-13:1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |